Navidea Biopharmaceuticals' NAV4694 beta-amyloid imaging candidate has demonstrated promising performance in a new study, according to the company. Researchers compared the agent with C-11 Pittsburgh Compound B in postmortem examinations of brain tissue. "This study indicated that unlike PiB, the benchmark PET amyloid agent, NAV4694 was capable of differentiating controls from AD in all brain regions and also exhibited a wider dynamic range and fewer false negatives as compared to gold-standard pathology," said researcher Dr. Pedro Rosa-Neto.

Full Story:

Related Summaries